恒瑞医药：公司前瞻性地广泛布局多个治疗领域，并向纵深发展

Core Viewpoint - Heng Rui Medicine (600276) is strategically expanding its presence across multiple therapeutic areas, focusing on long-term diversified growth through a robust R&D pipeline in oncology and other fields [1] Group 1: Strategic Development - The company has a comprehensive layout in various treatment areas, including oncology, metabolic and cardiovascular diseases, immunology, respiratory diseases, and neuroscience [1] - Heng Rui Medicine is committed to a differentiated R&D strategy that is guided by clinical needs, utilizing advanced technology platforms to develop a highly differentiated innovative product matrix [1] Group 2: Global Expansion and Collaboration - The company plans to accelerate its global expansion steadily and deepen external collaborations to enhance its overseas R&D capabilities [1] - There is a focus on strengthening commercialization capabilities in both domestic and international markets to maximize the global market potential of high-quality innovative products [1]